VIDEO: Pipeline heralds 'exciting' years ahead for DME

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I think the pipeline looks really pretty good. There’s essentially additional targets that they’re looking at. There’s different entire platforms to deliver a drug. And right now, a lot of that late-stage pipeline has now come into clinical practice in the form of alibercept at 8 mg. And so, I certainly think that it’s going to be a really, really exciting next couple of years. But I would also say, you know, there’s now more and more drugs targeting diabetic retinopathy and the progression of diabetic retinopathy, and this is going to be really interesting as GLP-1 agonists start to become more mainstream treatment in diabetes. And the question is, is there going to be the same level of marketplace for these drugs that there was once? Hopefully the answer is with really improved HbA1cs, we can move a lot of our patients in the United States away from severe NPDR, proliferative diabetic retinopathy and associated complications.